Core Viewpoint - The company, Hangzhou Botao Biotechnology Co., Ltd., anticipates a decline in revenue and net profit for 2025 due to the impact of U.S. tariff policies and cyclical fluctuations in the infectious disease market, but expects steady growth in 2026 with new product registrations and strategic investments in the brain-computer interface (BCI) industry [1][2]. Financial Performance - The company forecasts a significant drop in net profit for 2025, primarily due to revenue declines from U.S. tariffs and cyclical market demand fluctuations, alongside increased R&D and stock incentive costs [2]. - Despite short-term performance pressures, the company is optimistic about 2026 being a turning point for revenue and profit growth, supported by new product registrations and stable tariff conditions [2]. Product Development and Innovation - The company is accelerating the development of its microfluidic technology platform, focusing on cardiac markers, thyroid function, and nutrition-related projects, with breakthroughs in multi-project detection on a single chip [2]. - The company has received FDA510(k) approval for fentanyl testing and is progressing with various microfluidic product registrations in China, the EU, and Southeast Asia [2]. Strategic Expansion in Brain-Computer Interface - The company is actively investing in the BCI sector, aiming to establish it as a second core business through direct investments and partnerships [3]. - A strategic investment in Hangzhou Qingshi Yongjun has been made, focusing on invasive BCI treatments for treatment-resistant depression, with clinical trials already underway [3][4]. - The company has also invested in Hangzhou Haoshi Tianhui, which focuses on non-invasive BCI technologies for mental health assessments, with plans for product promotion and sales in 2026 [5][6]. Industry Ecosystem Development - The company plans to establish a specialized industry fund for the BCI sector, with a total scale of 200 million yuan, to enhance collaboration and development within the medical device ecosystem [6]. - The company is committed to building a synergistic medical device ecosystem in the BCI industry, recognizing it as a long-term investment opportunity in the healthcare sector [6].

Core Viewpoint - The company has strategically invested in Hangzhou Haoshi Tianhui Technology Co., Ltd., acquiring a 16% stake as the sole investor in its latest financing round, marking another exploration in the non-invasive brain-computer interface sector following its 2025 investment in Qingshi Yongjuan [1] Group 1: Company Overview - Haoshi Tianhui is an innovative high-tech enterprise focused on artificial intelligence in the medical field, with a founding team that has overseas entrepreneurial experience and strong industry expertise [1] - The company has developed a diverse product matrix that includes applications in mental health, cardiovascular monitoring, and imaging diagnostics [1] Group 2: Product and Technology - Haoshi Tianhui's self-developed medical-grade non-invasive brain-computer interface and mental health assessment devices can accurately evaluate emotional issues such as depression and anxiety, integrating music therapy interventions into a comprehensive service model [1] - The products are designed for various settings, including hospitals, schools, health check centers, and mental health institutions, providing objective and efficient assessments compared to traditional evaluation methods [1] Group 3: Regulatory and Market Plans - The company obtained a Class II medical device registration certificate in November 2025 for its products aimed at detecting mental health issues, with plans to promote and sell these products in the domestic market starting in 2026 [1]

Core Insights - The investment agreement between Botao Bio's subsidiary Botai Zhito and Hangzhou Haoshi Tianhui marks a significant step in the brain-computer interface (BCI) industry, enhancing the commercial viability of the sector [1][2] Group 1: Investment and Strategic Development - Botai Zhito has completed a strategic investment in Haoshi Tianhui, becoming the sole investor in this financing round [1] - This investment complements Botao Bio's previous strategic stake in Qingshi Yongjun, establishing a dual technology path in both invasive and non-invasive BCI [2] Group 2: Company and Product Overview - Haoshi Tianhui is an innovative high-tech enterprise focused on AI in healthcare, with a strong founding team possessing overseas entrepreneurial experience and deep technical expertise [2] - The company's core AI and non-invasive BCI products aim to create a closed-loop service for various mental health issues, including depression and anxiety, through assessment, intervention, and feedback [2] Group 3: Financial Projections - Revenue forecasts for the company from 2025 to 2027 are projected at 496 million, 693 million, and 887 million yuan, reflecting a year-on-year change of -11.42%, +39.78%, and +28.11% respectively [3] - The net profit attributable to the parent company is expected to be 60 million, 158 million, and 215 million yuan for the same period, with year-on-year changes of -64.49%, +162.50%, and +35.95% respectively [3]